Patents Represented by Attorney, Agent or Law Firm Martha A. Gammill
-
Patent number: 8247211Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.Type: GrantFiled: February 8, 2011Date of Patent: August 21, 2012Assignees: American Cyanamid Company, Wyeth Holdings CorporationInventors: Jason Arnold Lotvin, Mark Edward Ruppen
-
Patent number: 8227235Abstract: Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of Saccharomyces cerevisiae, Bacillus licheniformis or Bacillus subtilis spores, and a carrier. Also included are animal feed compositions including the composition for the prevention, control and/or treatment of a disease in an animal and an animal's food/feed. The compositions are useful to prevent, control, and treat diseases such as necrotic enteritis in poultry when used in combination with an anticoccidal ionophore or coccidiosis vaccine.Type: GrantFiled: September 21, 2009Date of Patent: July 24, 2012Assignee: Alpharma, LLCInventors: James Skinner, Doug Rupp
-
Patent number: 8158579Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: GrantFiled: November 30, 2010Date of Patent: April 17, 2012Assignee: BioRexis Pharmaceutical CorporationInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 7622500Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, compositions containing such compounds and the uses of such compounds as antiparasitic agents.Type: GrantFiled: February 20, 2008Date of Patent: November 24, 2009Assignee: Pfizer LimitedInventors: Stephen Paul Gibson, Christelle Lauret
-
Patent number: 7608604Abstract: The present invention relates to compounds of the formula (I) or a tautomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, tautomer or prodrug, wherein: R1, R2, R3, R4 and R5 are each independently selected from H, halo, CN, CF3 and CONH2; compositions containing such compounds and the uses of such compounds as antiparasitic agents.Type: GrantFiled: February 8, 2008Date of Patent: October 27, 2009Assignee: Pfizer LimitedInventors: Stuart Nicholas Comlay, Joanne Clare Hannam, William Howson, Christelle Lauret, Yogesh Anil Sabnis
-
Patent number: 7407654Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: GrantFiled: October 4, 2002Date of Patent: August 5, 2008Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 7211565Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.Type: GrantFiled: March 15, 2004Date of Patent: May 1, 2007Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Buttner, Isabelle Cornut, Gunther Metz
-
Patent number: 7189411Abstract: The invention relates to the formation of peptide/lipid vesicles and complexes through the co-lyophilization of peptides, preferably that are able to adopt an amphipathic alphahelical conformation, and one or more lipids. A single solution which solubilizes both the peptides and lipids or two separate solutions may be lyophilized.Type: GrantFiled: September 23, 2002Date of Patent: March 13, 2007Assignee: Jean-Louis DasseuxInventor: Jean-Louis Dasseux
-
Patent number: 7157425Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.Type: GrantFiled: March 15, 2002Date of Patent: January 2, 2007Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz
-
Patent number: 6664291Abstract: The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.Type: GrantFiled: March 28, 2001Date of Patent: December 16, 2003Assignee: Pfizer, Inc.Inventors: Yuan-Ching P. Chiang, Gary E. Aspnes, Kimberly G. Estep
-
Patent number: 6657063Abstract: This invention is directed to pharmaceutical compositions comprising &bgr;3 adrenergic agonists including (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid and growth hormone or growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of using those compositions in the treatment of obesity, diabetes, hypertension and frailty in animals and particularly in humans.Type: GrantFiled: August 28, 2000Date of Patent: December 2, 2003Assignee: Pfizer Inc.Inventor: Robert L. Dow
-
Patent number: 6589947Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.Type: GrantFiled: October 26, 2000Date of Patent: July 8, 2003Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Ernest S. Hamanaka, Yuhpyng Liang Chen
-
Patent number: 6545018Abstract: The present invention provides novel compounds of the Formula and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1-R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease, hypothyroidism and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis are also provided.Type: GrantFiled: September 27, 2001Date of Patent: April 8, 2003Assignee: Pfizer Inc.Inventors: Yuan-Ching Phoebe Chiang, Robert L. Dow
-
Patent number: 6518431Abstract: A process for preparing a compound of the formula wherein n, R1, R2, R3 and X are as defined above, used as an intermediate in the synthesis of &bgr;-adrenergic receptor agonists.Type: GrantFiled: March 28, 2001Date of Patent: February 11, 2003Assignee: Pfizer Inc.Inventors: Robert L. Dow, Steven R. Schneider
-
Patent number: 6465651Abstract: This invention relates to a process for preparing compounds of the Formula I, wherein R1, R2 and Pt are as defined in the specification, which are intermediates in the synthesis of certain growth hormone secretagogue compounds. This invention further relates to processes for preparing the growth hormone secretagogues. The invention also relates to the compound of Formula I wherein R1 is H, R2 is 2,2,2-trifluoromethyl and Pt is Boc.Type: GrantFiled: August 3, 2001Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: Charles K. Chiu, David A. Griffith
-
Patent number: 6448263Abstract: This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I.Type: GrantFiled: August 26, 1999Date of Patent: September 10, 2002Assignee: Pfizer Inc.Inventors: Philip Albert Carpino, Charles Kwok-Fung Chiu, Lydia Codetta Pan, Bruce Allen Lefker, Judith Lee Treadway, Michael Paul Zawistoski
-
Patent number: 6380223Abstract: The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.Type: GrantFiled: April 27, 2000Date of Patent: April 30, 2002Assignee: Pfizer Inc.Inventors: Robert L. Dow, Kevin K. Liu, Bradley P. Morgan, Andrew G. Swick
-
Patent number: 6358951Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery, improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: August 18, 1999Date of Patent: March 19, 2002Assignee: Pfizer Inc.Inventor: Philip A. Carpino
-
Patent number: 6297380Abstract: This invention relates to a process for preparing compounds of the Formula I, wherein R1, R2 and Pt are as defined in the specification, which are intermediates in the synthesis of certain growth hormone secretagogue compounds. This invention further relates to processes for preparing the growth hormone secretagogues. The invention also relates to the compound of Formula I wherein R1 is H, R2 is 2,2,2-trifluoromethyl and Pt is Boc.Type: GrantFiled: November 12, 1999Date of Patent: October 2, 2001Assignee: Pfizer Inc.Inventors: Charles K. Chiu, David A. Griffith
-
Patent number: 6291489Abstract: This invention relates to processes for preparing compounds of the formula (I) and to processes for preparing certain intermediates of the formula wherein R1 is nitro, amino or protected amino; R2 is H, fluoro, chloro CF3, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, amino or protected amino; and X1 is OH or a suitable leaving group, used in that process. The invention also relates novel to compounds of the formulae (II).Type: GrantFiled: May 5, 1999Date of Patent: September 18, 2001Assignee: Pfizer Inc.Inventors: Keith M DeVries, Robert L. Dow, Stephen W. Wright